{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:01Z","timestamp":1740120061204,"version":"3.37.3"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["201964"],"award-info":[{"award-number":["201964"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clinthera.2019.04.007","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T14:33:43Z","timestamp":1557239623000},"page":"1110-1127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects"],"prefix":"10.1016","volume":"41","author":[{"given":"Malek","family":"Okour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeep","family":"Puri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Port","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Berni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Khindri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tenero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.04.007_bib1","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ehj.2004.09.014","article-title":"Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the european society of cardiology","volume":"25","author":"Galie","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2019.04.007_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5603\/PiAP.a2015.0084","article-title":"Pulmonary arterial hypertension: a current review of pharmacological management","volume":"84","author":"Sahni","year":"2016","journal-title":"Pneumonologia i alergologia polska"},{"key":"10.1016\/j.clinthera.2019.04.007_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2019.04.007_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2019.04.007_bib5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1183\/09031936.00101211","article-title":"Survival in pulmonary hypertension in Spain: insights from the Spanish registry","volume":"40","author":"Escribano-Subias","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2019.04.007_bib6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2019.04.007_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2466-14-45","article-title":"Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry","volume":"14","author":"Jansa","year":"2014","journal-title":"BMC Pulm Med"},{"issue":"25 Suppl","key":"10.1016\/j.clinthera.2019.04.007_bib8","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2019.04.007_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1513\/pats.201006-046WR","article-title":"Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 nef","volume":"8","author":"Almodovar","year":"2011","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.clinthera.2019.04.007_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.04.007_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A\u00a0novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2019.04.007_bib12","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2019.04.007_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.04.007_bib14","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"year":"2009","series-title":"Letairis: Highlights of Prescribing Information","author":"Food and Drug Administration","key":"10.1016\/j.clinthera.2019.04.007_bib15"},{"key":"10.1016\/j.clinthera.2019.04.007_bib16","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.amjcard.2017.06.012","article-title":"The nitric oxide pathway in pulmonary vascular disease","volume":"120","author":"Klinger","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2019.04.007_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2019.04.007_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2019.04.007_bib19","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"year":"2009","series-title":"Adcirca: Highlights of Prescribing Information","author":"Food and Drug Administration","key":"10.1016\/j.clinthera.2019.04.007_bib20"},{"key":"10.1016\/j.clinthera.2019.04.007_bib21","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1002\/jps.21789","article-title":"No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers","volume":"98","author":"Spence","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.clinthera.2019.04.007_bib22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2019.04.007_bib23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-2600(16)30307-1","article-title":"Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"article-title":"Guideline on the investigation of bioequivalence","year":"2010","series-title":"CHMP) CFMPFHU","key":"10.1016\/j.clinthera.2019.04.007_bib24"},{"key":"10.1016\/j.clinthera.2019.04.007_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2125.2005.02553.x","article-title":"Tadalafil pharmacokinetics in healthy subjects","volume":"61","author":"Forgue","year":"2006","journal-title":"Br J Clin Pharmacol"},{"year":"2008","key":"10.1016\/j.clinthera.2019.04.007_bib26"},{"key":"10.1016\/j.clinthera.2019.04.007_bib27","first-page":"11","article-title":"A\u00a0review of pulmonary arterial hypertension: role of ambrisentan","volume":"3","author":"Barst","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2019.04.007_bib28","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1177\/0091270008324180","article-title":"Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers","volume":"48","author":"Spence","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.04.007_bib29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.2009.03384.x","article-title":"The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers","volume":"67","author":"Walker","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.04.007_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3999\/jscpt.41.301","article-title":"Pharmacokinetics of ambrisentan, a novel drug for treatment of pulmonary arterial hypertension (PAH), in Japanese subjects","volume":"41","author":"Nakahara","year":"2010","journal-title":"Rinsho yakuri Jpn J Clin Pharmacol Ther"},{"issue":"suppl_H","key":"10.1016\/j.clinthera.2019.04.007_bib31","doi-asserted-by":"crossref","first-page":"H32","DOI":"10.1016\/S1520-765X(02)90050-7","article-title":"Overview of the cardiovascular effects of tadalafil","volume":"4","author":"Emmick","year":"2002","journal-title":"Eur Heart J supplements"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T20:40:54Z","timestamp":1565124054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819301717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0149291819301717"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}